Expert perspectives on cholangiocarcinoma (CCA)

Molecular profiling: Challenges and opportunities in cholangiocarcinoma (ILCA 2022)

Dr Teresa Macarulla

Vall d’Hebron University Hospital,
Barcelona, Spain

Dr Daniel Kazdal

Centre for Molecular Pathology,
University Hospital Heidelberg,
Heidelberg, Germany

Dr Ana Vivancos

Vall d’Hebron Institute of Oncology,
Barcelona, Spain

Dr Angela Lamarca

Fundación Jiménez Díaz University Hospital, Spain

Professor John Bridgewater

Clinical Professor, University College London Cancer Institute, London, UK

Dr Nicola Normanno

Istituto Nazionale per lo Studio e la Cura dei Tumori. Fondazione G. Pascale, Italy

Dr Angela Lamarca

Fundación Jiménez Díaz University Hospital, Spain

Company/Organisation	Relationship(s)
Ability Pharmaceuticals SL, Aptitude Health, AstraZeneca, Basilea Pharma, Baxter, BioLineRX Ltd, Celgene, Eisai, Ellipses, Genzyme, Got It Consulting SL, Hirslanden/GITZ, Imedex, Incyte, Ipsen Bioscience Inc, Janssen, Lilly, Marketing Farmacéutico & Investigación Clínica S.L, MDS, Medscape, Novocure, Paraxel, Polaris, PPD Development, QED Therapeutics, Roche Farma, Sanofi-Aventis, Scilink Comunicación Científica SC, Servier, Surface Oncology, Swedish Orphan Biovitrum AB, Zymeworks	Advisory role Speaker’s fee Direct research fund
AbbVie Farmaceútica, Ability Pharmaceuticals, Agios Pharmaceuticals, Amc Medical Research, Amgen, Armo Biosciences, Aslan Pharmaceuticals, Astrazeneca, Basilea Pharmaceutica International, Bayer, Beigene, Biokeralty Research Institute, Biolinerx, Blueprint Medicines, Boston Biomedical, Bristol-Myers Squibb (BMS), Cantargia, Celgene, Eisai, Erytech Pharma, F. Hoffmann-la Roche, Fibrogen, Halozyme, Incyte, Ipsen Bioscience, Ipsen Pharma, Lilly, Loxo Oncology, Medimmune, Merck Sharp & Dohme, Nelum, Novartis, Novocure, Oncomed Pharmaceuticals, QED Therapeutics, VCN Biosciences, Zymeworks	Clinical trial support

Company/Organisation	Relationship(s)
Personal funding	Agilent, AstraZeneca, Bristol Myers Squibb, Incyte, Lilly, Pfizer, Takeda

Company/Organisation	Relationship(s)
Bayer, BMS, Guardant Health, Incyte, Merck, Novartis, Roche	Advisory board

Company/Organisation	Relationship(s)
Albireo Pharma, AstraZeneca, Boehringer Ingelheim, Boston Scientific, Eisai, GenFit, Nutricia Ipsen, QED, Roche, Servier and TransThera Biosciences	Receipt of honoraria or consultation fees
AAA, AstraZeneca, Eisai, Incyte, Ipsen, Merck, Pfizer, QED, Roche and Servier	Participation in company-sponsored speaker bureau
AAA, Bayer, Delcath, Ipsen, Mylan, Novartis, Pfizer and Sirtex	Travel, education funding
Ipsen and Roche	Research funding

Company/Organisation	Relationship(s)
Amgen, AstraZeneca, Basilea, Bayer, Bristol-Myers Squibb, Celgene, Incyte, Medarex, Merck Serono, MSD Oncology, Roche, Servier	Support

Disclosures

Dr Nicola Normanno:

Company/Organisation	Relationship(s)
MSD, Qiagen, Bayer, Biocartis, Illumina, Incyte, Roche, BMS, Merck, Thermo Fisher, Boehringer Ingelheim, AstraZeneca, Sanofi, Eli Lilly	Personal financial interests (speaker’s fee and/or advisory boards)
Merck, Sysmex, Thermo Fisher, QIAGEN, Roche, AstraZeneca, Biocartis, Illumina	Institutional financial interests (financial support to research projects)
President, International Quality Network for Pathology (IQN Path); President, Italian Cancer Society (SIC)	Non-financial interests